These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: [Prospective observational study of clinical course after stopping inhaled corticosteroids in child asthma].
    Author: Akasawa A, Suda T, Akashi M, Narita M, Ohya Y, Manki A, Watanabe H, Kumaki M, Matsumoto K, Saito H.
    Journal: Arerugi; 2009 Oct; 58(10):1407-17. PubMed ID: 19901510.
    Abstract:
    BACKGROUND: Prospective study was carried out to observe the clinical course and find out the clinical index to predict the outcome after stopping of inhaled corticosteroids (ICS). SUBJECTS: One hundred twelve asthmatic children (aged 12.9+/-9.6 years old) who were totally controlled with 100 microg/day of inhaled corticosteroids and have not experienced asthma symptom over 3 months, were enrolled. METHODS: Patients with over PC20 0.5 mg/mL of methacholine challenge test (MCT) were recommended to stop ICS therapy. Clinical course, lung function and bronchial hyperreactivity were followed at 7, 16 and 24 months after stopping of ICS. RESULTS: Eighty-one percent of 63 patients followed up to 24 months run on as symptom less than one time per month without remarkable change of lung function. PC20 in group of no asthma symptom during 24 months (group A) decreased weakly. That of other groups decreased remarkably. Days using ICS and plasma IgE antibody at stopping of ICS were different in clinical course at 24 months after stopping ICS. CONCLUSION: Over 80% of totally controlled asthmatic children with MCT PC20 over 0.5 mg/mL could stop ICS therapy and run on without relapse.
    [Abstract] [Full Text] [Related] [New Search]